Evia

Research Article

PT-141 -: PT-141 Palatin.

Palatin, under license from Competitive Technology, is developing the peptide PT-141, a synthetically modified analog of PT-14, as a nasal spray for the potential treatment of erectile dysfunction (ED) and female sexual dysfunction. In September 2003, Palatin had completed a phase IIb trial in patients with ED and in February 2004, Palatin planned to start phase III trials in early 2005.

Study context

Study design
Clinical trial
Population or model
Human participants; verify the population in the source

Research question

What does this source report about PT-141 -, and what evidence model and limitations apply?

Limitations

Confirm the complete study design, intervention identity, population or model, outcomes, statistical context, and limitations in the linked source before approval.

Original source

PT-141 Palatin.

Petter Hedlund · Current opinion in investigational drugs (London, England : 2000) · 2004

PMID 15134289human
Source abstract

Palatin, under license from Competitive Technology, is developing the peptide PT-141, a synthetically modified analog of PT-14, as a nasal spray for the potential treatment of erectile dysfunction (ED) and female sexual dysfunction. In September 2003, Palatin had completed a phase IIb trial in patients with ED and in February 2004, Palatin planned to start phase III trials in early 2005.

Open source record

Related product

Review the complete product page, COAs, specifications, and all approved research sources.

PT-141 - 10mg research page

This educational summary helps you review the cited source in context. The third-party article is not reproduced, and the citation does not imply endorsement of a related product.